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Abstract 
Background: The chemokine receptor CXCR4 is frequently overexpressed and associated with adverse prognosis in 
most hematopoietic malignancies and solid cancers. Recently, CXCR4 molecular imaging using the CXCR4‑specific 
positron emission tomography (PET) tracer Pentixafor  ([68Ga]Pentixafor) has become a well‑established method to 
non‑invasively measure CXCR4 expression in vivo. In previous Pentixafor imaging studies, highly variable CXCR4 tracer 
uptake to the spleen was observed.
Results: We investigated the hypothesis that enhanced spleen  [68Ga]Pentixafor uptake and thus CXCR4 expression in 
patients with solid tumors would indicate an activated spleen state and/or an association with clinical and prognostic 
features and survival parameters. In this retrospective study,  [68Ga]Pentixafor‑PET images and patient records of 145 
solid tumor patients representing 27 cancer entities were investigated for an association of spleen  [68Ga]Pentixafor 
uptake and clinical characteristics and outcome. Based on this assessment, we did not observe differences in clinical 
outcomes, measured by progression‑free survival, overall survival and remission status neither within the entire cohort 
nor within subgroups of adrenal cancer, desmoplastic small round cell tumor, neuroendocrine tumors, non‑small cell 
lung cancer, small cell lung cancer and pancreatic adenocarcinoma patients. No tumor entity showed especially high 
levels of spleen  [68Ga]Pentixafor uptake compared to others or a control cohort. However, when investigating labora‑
tory parameters, there was a positive correlation of high spleen  [68Ga]Pentixafor uptake with leukocyte and/or platelet 
counts in neuroendocrine tumors, non‑small cell lung cancer and small cell lung cancer.
Conclusion: Spleen  [68Ga]Pentixafor uptake was not associated with stage of disease and clinical outcomes in solid 
tumor patients. We identified positively associated platelet and/or leukocyte counts with spleen  [68Ga]Pentixafor 
uptake in neuroendocrine tumors, non‑small cell lung cancer and small cell lung cancer, suggesting that splenic 
CXCR4 expression could possibly play a role in systemic immunity/inflammation in some types of solid tumors or a 
subgroup of patients within solid tumor entities.
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Background
C-X-C motif chemokine receptor type 4 (CXCR4) and its 
main ligand stromal cell-derived factor 1 (SDF-1), have 
pivotal roles in hematopoiesis, cardiovascular develop-
ment and homing of immune cells [1–3]. Thus, physi-
ologically CXCR4 is highly expressed on hematopoietic 
cells such as B and T cells [2, 4]. In malignancies, CXCR4 
has been shown to be overexpressed as compared to 
non-malignant control tissue and, moreover, to be asso-
ciated with adverse prognosis in many different types 
of cancer [5–9], suggesting a role of CXCR4 as a tumor 
driver. Additionally, there is a plethora of data elucidating 
the critical function and likely complex role of CXCR4 
for microenvironment, metastasis and dissemination 
of tumors [10–13].  [68Ga]Pentixafor positron emission 
tomography (PET) is a well-established method to image 
CXCR4 expression of hematopoietic and solid tumors 
in vivo [14–16] and previous studies with  [68Ga]Pentixa-
for have revealed a wide heterogeneity of tumor CXCR4 
expression within different entities of cancer [17–19]. 
Furthermore, in some entities, patients with high levels 
of tumor  [68Ga]Pentixafor uptake exhibited unfavorable 
outcomes [20]. During previous studies in solid tumor 
patients using  [68Ga]Pentixafor, we observed a wide vari-
ance not only of tumor, but also spleen CXCR4 expres-
sion [21]. In recent years, evidence of the importance of 
not only the local tumor microenvironment, but also the 
impact of systemic immunity on the suppression of anti-
tumor immune responses and hence tumor progression 
has accumulated, shedding light on more complex inter-
actions between tumor cells and primary as well as sec-
ondary lymphoid organs [22–24]. Various solid tumors 
for instance induce tumor-associated extra-medullary 
hematopoiesis in the spleen, associated with adverse 
patient outcomes [25, 26]. Furthermore, suppression of 
anti-tumor immunity is, along with other complex mech-
anisms, majorly regulated through immunosuppressive 
myeloid-derived suppressor cells (MDSCs), which origi-
nate in the spleen [27–29]. Tumor infiltrating MDSCs are 
known to express high levels of CXCR4 and to migrate 
towards a SDF-1 gradient [30, 31]. Splenic MDSCs are 
known to express CXCR4 as well, but the role of CXCR4 
in the spleen for MDSC differentiation and release to 
peripheral sites remains unclear. Taken together, there 
is strong evidence that underlines the pivotal roles of the 
spleen and CXCR4 in the immune response to tumors. 
Hence, we hypothesized one explanation for the variabil-
ity of spleen CXCR4 expression in solid tumor patients 
could potentially be an activated state of spleen, through 
tumor-related effects, associated with suppression of 
anti-tumor immunity and potentially adverse clinical 
outcomes. To this point, no large study investigating 
CXCR4 enrichment in spleens of solid tumor patients has 
been conducted and the relevance of these differences 
for clinical outcomes remains unclear. Thus, we aimed to 
investigate and report a large retrospective analysis eval-
uating clinical outcomes and laboratory parameters in 
relation to spleen CXCR4 expression of 145 patients with 
solid tumors and 5 control patients, which had previously 
been imaged with the CXCR4-specific PET tracer  [68Ga]
Pentixafor.
Results
Patient and control cohorts and their primary 
characteristics
We retrospectively included 145 solid tumor patients in 
this study, which had previously undergone imaging with 
 [68Ga]Pentixafor-PET/computed tomography (CT). Fur-
thermore, we included 5 control patients, of whom 3 were 
diagnosed with Conn’s adenoma and 2 were diagnosed as 
healthy. The group of tumor patients comprised 27 dif-
ferent entities and the largest groups of patients included 
31 adrenal cancers, 25 neuroendocrine tumors, 13 small 
cell lung cancers (SCLC), 9 desmoplastic small round cell 
tumors (DSRCT), 9 pancreatic adenocarcinomas and 9 
non-small cell lung cancers (NSCLC). In this cohort, 89 
(61.4%) patients were male and 56 (38.6%) female and 
the mean age was 58.8 ± 14.7 years. At the time of  [68Ga]
Pentixafor-PET imaging 28 (19.3%) patients had limited 
stage of disease (T1/T2 without distant metastasis) and 
62 (42.8%) patients advanced disease stage (T3/T4 or dis-
tant metastases). In 55 (37.9%) patients, the exact stage of 
disease at the time of imaging could not be determined 
retrospectively (Table 1).
Spleen  [68Ga]Pentixafor uptake levels show a great 
variance and are not associated with prior systemic 
treatment
We determined the maximum standardized uptake 
value (SUV) for  [68Ga]Pentixafor of patients’ spleens 
 (SUVmaxSpleen). Patients showed a great vari-
ance of splenic  [68Ga]Pentixafor uptake with a mean 
 SUVmaxSpleen of 8.50 ± 4.67 (range, 2.00–56.00). To rule 
out differences in uptake, we decided to normalize spleen 
uptake, by dividing the maximum splenic  [68Ga]Pentixa-
for uptake by the mean hepatic uptake, therefore using 
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the liver as a reference organ  (SUVmaxSpleen/SUVmean-
Liver; spleen-to-liver ratio, SLR) and used this param-
eter for further analysis of spleen CXCR4 expression. The 
mean SLR was 6.19 ± 2.28 (range, 0.77–16.44). Examples 
of patients with low and high SLR are given in Fig. 1.
As we observed solid cancer patients with very high and 
such with low spleen  [68Ga]Pentixafor uptake expression, 
we sought to address the question, whether some solid 
tumor entities were associated with notably higher lev-
els of chemokine receptor expression. To address this, we 
selected all tumor entities for which  [68Ga]Pentixafor-PET 
images of at least 4 patients were available to us and com-
pared PET-derived SLR. We detected minor differences in 
mean expression levels but could not define tumor enti-
ties with especially high levels of spleen  [68Ga]Pentixafor 
uptake compared to others (Fig. 2A). However, we observed 
a great variance of spleen  [68Ga]Pentixafor uptake within 
each tumor type, identifying patients within entities with 
manifold higher uptake compared to other patients with 
the same disease (Fig.  2A). Further, we hypothesized that 
systemic treatment could potentially influence receptor 
expression. Hence, we compared prior systemically treated 
patients to those who had not undergone treatment before 
imaging. We did not see any changes of spleen  [68Ga]Pentix-
afor uptake in association with systemic treatment (Fig. 2B).
Spleen  [68Ga]Pentixafor uptake is not associated 
with clinical outcomes
From the observed wide variance of spleen CXCR4 
expression levels, the question emerged, whether these 
Table 1 Primary characteristics of patients and controls
Table indicates the number of patients and control patients (n) separated by type of tumor entity, indicating the respective number and frequency of male and female 
patients (n/%), mean age of patients in years (mean ± SD) as well as the number and frequency of patients with limited, advanced and unknown tumor stage (n/%)
Entity n Male (n/%) Female (n/%) Age (mean ± SD) Stage limited/advanced/unknown (n/%)
All tumors 145 89 (61.4%) 56 (38.6%) 58.8 ± 14.70 28 (19.3%)/62 (42.8%)/55 (37.9%)
 Adrenal cancers 31 13 (41.9%) 18 (58.1%) 51.3 ± 9.97 5 (16.1%)/19 (61.3%)/7 (22.6%)
 Atypical carcinoid of lung 1 0 (0.0%) 1 (100.0%) 58.0 ± 0.00 0 (0.0%)/0 (0.0%)/1 (100.0%)
 Breast cancer (non‑neuroendocrine) 2 0 (0.0%) 2 (100.0%) 59.5 ± 1.50 0 (0.0%)/0 (0.0%)/2 (100.0%)
 Cholangiocarcinoma 4 3 (75.0%) 1 (25.0%) 70.3 ± 5.17 1 (25.0%)/2 (50.0%)/1 (25.0%)
 Colorectal cancer 1 1 (100.0%) 0 (0.0%) 60.0 ± 0.00 1 (100.0%)/0 (0.0%)/0 (0.0%)
 CUP (non‑neuroendocrine) 3 1 (33.3%) 2 (66.7%) 74.3 ± 8.06 0 (0.0%)/2 (66.7%)/1 (33.3%)
 DSRCT 9 9 (100.0%) 0 (0.0%) 29.4 ± 8.90 0 (0.0%)/0 (0.0%)/9 (100.0%)
 Ewing’s sarcoma 1 1 (100.0%) 0 (0.0%) 53.0 ± 0.00 0 (0.0%)/1 (100.0%)/0 (0.0%)
 Granulosa cell tumor 1 0 (0.0%) 1 (100.0%) 72.0 ± 0.00 1 (100.0%)/0 (0.0%)/0 (0.0%)
 Hepatocellular carcinoma 6 3 (50.0%) 3 (50.0%) 61.3 ± 7.16 3 (50.0%)/1 (16.7%)/2 (33.3%)
 Laryngeal cancer 1 1 (100.0%) 0 (0.0%) 72.0 ± 0.00 0 (0.0%)/0 (0.0%)/1 (100.0%)
 Malignant paraganglioma 1 1 (100.0%) 0 (0.0%) 49.0 ± 0.00 0 (0.0%)/1 (100.0%)/0 (0.0%)
 MANEC 2 1 (50.0%) 1 (50.0%) 65.5 ± 2.50 0 (0.0%)/2 (100.0%)/0 (0.0%)
 Melanoma 2 2 (100.0%) 0 (0.0%) 66.0 ± 4.00 0 (0.0%)/0 (0.0%)/2 (100.0%)
 Mesothelioma 6 5 (83.3%) 1 (16.7%) 69.3 ± 9.59 1 (16.7%)/2 (33.3%)/3 (50.0%)
 Neuroendocrine tumors 25 17 (68.0%) 8 (32.0%) 66.3 ± 10.57 3 (12.0%)/14 (56.0%)/8 (32.0%)
 NSCLC 9 8 (88.9%) 1 (11.1%) 59.3 ± 8.56 4 (44.4%)/5 (55.6%)/0 (0.0%)
 Osteosarcoma 1 1 (100.0%) 0 (0.0%) 32.0 ± 0.00 1 (100.0%)/0 (0.0%)/0 (0.0%)
 Ovarial cancer 1 0 (0.0%) 1 (100.0%) 73.0 ± 0.00 1 (100.0%)/0 (0.0%)/0 (0.0%)
 Pancreatic adenocarcinoma 9 6 (66.7%) 3 (33.3%) 65.3 ± 12.89 2 (22.2%)/1 (11.1%)/6 (66.7%)
 Prostate cancer 2 2 (100.0%) 0 (0.0%) 64.0 ± 8.00 0 (0.0%)/1 (50.0%)/1 (50.0%)
 Renal cell carcinoma 4 3 (75.0%) 1 (25.0%) 71.8 ± 12.75 1 (25.0%)/2 (50.0%)/1 (25.0%)
 Sarcoma 7 3 (42.9%) 4 (57.1%) 45.7 ± 18.90 2 (28.6%)/1 (14.3%)/4 (57.1%)
 Salivary gland cancer 1 1 (100.0%) 0 (0.0%) 52.0 ± 0.00 0 (0.0%)/0 (0.0%)/1 (100.0%)
 SCLC 13 6 (46.2%) 7 (53.8%) 62.2 ± 11.41 2 (15.4%)/7 (53.8%)/4 (30.8%)
 Thyroid cancer 1 1 (100.0%) 0 (0.0%) 61.0 ± 0.00 0 (0.0%)/1 (100.0%)/0 (0.0%)
 Undifferentiated cancer of thymus 1 0 (0.0%) 1 (100.0%) 41.0 ± 0.00 0 (0.0%)/0 (0.0%)/1 (100.0%)
Controls
 Conn’s adenom 3 3 (100.0%) 0 (0.0%) 57.7 ± 7.93 n.a
 Healthy controls 2 1 (50.0%) 1 (50.0%) 65.5 ± 2.50 n.a
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differences were associated with patients’ clinical out-
comes. Thus, we compared progression-free survival (PFS) 
and overall survival (OS) by separating all patients accord-
ing to the median SLR for  [68Ga]Pentixafor into two groups 
of low and high spleen CXCR4 expression. When compar-
ing these groups, we saw similar probabilities of survival in 
both groups (Fig. 3A). Due to our approach of including all 
solid cancer patients, we faced a rather heterogenic com-
position of a variety of entities (Table 1). To rule out effects 
of differently proportioned allocation of entities to the two 
groups (low vs. high spleen  [68Ga]Pentixafor uptake) we 
separated patients within each tumor entity the same way, 
according to the median, whenever there were enough 
evaluable patients to compare at least 3 versus 3 patients 
in each expression group. Hence, we assessed survival in 
adrenal cancer, DSRCT, neuroendocrine tumor, NSCLC, 
pancreatic adenocarcinoma and SCLC patients. We could 
not observe significant differences in PFS/OS in aforemen-
tioned entities when comparing low vs. high spleen  [68Ga]
Pentixafor uptake (Additional file 1: Figure S1). Addition-
ally, we compared patients in the upper quartile of spleen 
CXCR4 expression to the lower quartile of all patients and, 
wherever possible, within entities and similarly observed 
no differences in PFS/OS (Additional file 1: Figure S2). We 
furthermore assessed whether disease remission was asso-
ciated with splenic  [68Ga]Pentixafor uptake. Hence, we 
compared the remission status of all patients and grouped 
patients into complete remission, partial remission, stable 
disease and progressive disease. Similar to the survival data, 
no differences in remission status could be seen in relation 
to spleen CXCR4 expression as measured by spleen  [68Ga]
Pentixafor uptake.
Elevated spleen  [68Ga]Pentixafor uptake is positively 
associated with leukocyte and/or platelet counts 
in neuroendocrine tumors, NSCLC and SCLC
We hypothesized differences in spleen CXCR4 expres-
sion measured by  [68Ga]Pentixafor-PET could potentially 
be associated with tumor metabolism/activity. Hence, 
we evaluated laboratory parameters of all patients from 
the day of imaging and correlated the respective SLR 
with serum C-reactive protein (CRP) (mg/dl), serum 
Fig. 1 Patients with solid tumors present with different levels of  [68Ga]Pentixafor uptake in spleen. A Representative image of a 68‑year‑old female 
patient presenting with hepatocellular carcinoma and low spleen CXCR4 expression as measured by  [68Ga]Pentixafor uptake. B Representative 
image of a 68‑year‑old male patient presenting with a neuroendocrine tumor and high spleen CXCR4 expression as measured by  [68Ga]Pentixafor 
uptake
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lactate-dehydrogenase (LDH) (U/l), hemoglobin levels (g/dl), peripheral leukocyte count (/nl) and peripheral 
Fig. 2 Spleen  [68Ga]Pentixafor uptake levels show a wide variety within different entities, and are not affected by systemic treatment. A 
Comparison of spleen‑to‑liver ratios  (SUVmaxSpleen/SUVmeanLiver) of patients with adrenal cancer, n = 31; cholangiocarcinoma, n = 4; DSRCT, n = 9; 
hepatocellular carcinoma, n = 6; mesothelioma, n = 6; neuroendocrine Tumors, n = 25; NSCLC, n = 9; pancreatic adenocarcinoma, n = 9; renal cell 
carcinoma, n = 4; sarcoma, n = 7; SCLC, n = 13 and control, n = 5. B Comparison of spleen‑to‑liver ratios  (SUVmaxSpleen/SUVmeanLiver) of patients of 
all tumor entities included in the study, comparing patients without ongoing (no systemic treatment, n = 85) to those with an ongoing systemic 
therapy or systemic treatment within the last month prior to imaging (systemic treatment, n = 63)
Fig. 3 Spleen  [68Ga]Pentixafor uptake does not correlate with clinical outcomes in solid tumor patients. A Kaplan–Meier survival curves of 
progression‑free survival (PFS) and overall survival (OS) of all solid tumor patients in the study separated by the median into two groups of low and 
high spleen‑to‑liver ratios  (SUVmaxSpleen/SUVmeanLiver), PFS: low, n = 61, high, n = 58; OS: low, n = 61, high, n = 54. B Comparison of spleen‑to‑liver 
ratios  (SUVmaxSpleen/SUVmeanLiver) with remission status of all patients, complete remission (CR), n = 2; partial remission (PR), n = 9; stable disease 
(SD), n = 15; progressive disease (PD), n = 51. All statistical analyses were performed using log rank (Mantel–Cox) test (A) and one‑way ANOVA with 
Tukey’s correction for multiple comparisons (B). P values as indicated on the graphs
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platelet count (/nl). When investigating serum CRP, 
serum LDH and hemoglobin levels, we could not detect 
any significant association with spleen  [68Ga]Pentixa-
for uptake (Additional file  1: Figures  S3–S6). However, 
in patients with neuroendocrine tumors and NSCLC we 
could observe a positive correlation of splenic  [68Ga]Pen-
tixafor uptake with peripheral blood leukocyte counts 
(neuroendocrine tumors: p = 0.0066; NSCLC: p = 0.0376; 
Fig.  4A). Furthermore, platelet counts correlated with 
receptor expression in neuroendocrine tumors and SCLC 
(neuroendocrine tumors: p = 0.0363; SCLC: p = 0.0261) 
and there was a trend of an association with platelet 
counts in adrenal cancer and NSCLC (adrenal cancer: 
p = 0.0697; NSCLC: p = 0.0748; Fig.  4B and Additional 
file  1: Figure  S7). Platelet counts were moreover associ-
ated with spleen  [68Ga]Pentixafor uptake independently 
of the tumor entity when analyzing the entire patient 
cohort (p = 0.0006; Additional file 1: Figure S3).
Discussion
There is some evidence implicating elevated serum CRP 
[32], elevated serum LDH [33, 34] and anemia [35] as 
markers for clinical outcomes in solid tumors. Further-
more, elevated leukocyte counts have been linked to 
unfavorable clinical outcomes in solid tumors [36–39] 
and thrombocytosis is associated with adverse outcomes 
in many cancers [40–42]. As for most patients the afore-
mentioned parameters were available, we investigated 
the hypothesis that elevated  [68Ga]Pentixafor uptake 
of spleen could be associated with an activated state of 
spleen and/or immune activity and clinical outcome. In 
our cohort, we could not discover significant correlations 
of serum CRP, serum LDH or blood hemoglobin levels 
with spleen  [68Ga]Pentixafor uptake. However, plate-
let counts were positively associated with splenic drug 
uptake, regardless of tumor entity. When investigating 
single entities, in patients with neuroendocrine tumors, 
NSCLC and SCLC platelet and/or leukocyte counts were 
positively associated with splenic uptake. In both entities 
imaging of CXCR4 using  [68Ga]Pentixafor was previously 
demonstrated to be feasible [21, 43, 44]. Furthermore, 
platelet counts showed a strong tendency of association 
in adrenal cancer and SCLC patients, too. Many data 
suggest tumors directly or indirectly stimulate throm-
bopoiesis through production of thrombopoietin (TPO) 
or interleukins [40, 45]. Interleukin 6 (IL-6) is among 
those interleukins most commonly elevated in the tumor 
microenvironment and has been shown to stimulate 
thrombopoiesis [46]. Furthermore, in different cell types, 
regulation of the release of IL-6 by the CXCR4/SDF-1 
Fig. 4 Spleen  [68Ga]Pentixafor uptake is positively associated with peripheral blood leukocyte and/or platelet counts in neuroendocrine 
tumors, NSCLC and SCLC. A Correlation of spleen‑to‑liver ratio  (SUVmaxSpleen/SUVmeanSpleen) with peripheral leucocyte count in patients with 
neuroendocrine tumors, n = 25 and NSCLC, n = 9. B Correlation of spleen‑to‑liver ratio  (SUVmaxSpleen/SUVmeanSpleen) with peripheral platelet count 
in patients with adrenal tumors, n = 31; neuroendocrine tumors, n = 25; NSCLC, n = 9 and SCLC, n = 13. All statistical analyses were performed using 
simple linear regression. R2 and P values as indicated on the graphs
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axis was demonstrated [47, 48]. CXCR4 and IL-6 are key-
regulators of inflammation and leucocyte migration in 
immunity and cancer [49, 50] and could potentially play 
a role in systemic immunity. Thus, spleen  [68Ga]Pentixa-
for uptake could possibly be a marker for spleen CXCR4 
expression and tumors with a higher inflammatory com-
ponent and tumors that rely more heavily on a functional 
tumor microenvironment that recruits platelets and leu-
kocytes. These complex regulatory mechanisms of the 
tumor microenvironment could also help to interpret 
lacking differences in serum CRP, serum LDH and hemo-
globin levels and explain why differences were not seen 
in all entities as the mechanisms involved might not be 
as relevant across different cancers or specifically in each 
patient’s tumors.
Additionally, we found no differences in survival out-
comes when investigating drug uptake to the spleen, 
indicating that splenic  [68Ga]Pentixafor uptake is not a 
single suitable parameter to predict patients’ outcomes. 
However, more entities could potentially show associa-
tions of splenic drug uptake with laboratory parameters 
or clinical outcome, as for many entities too few patients 
were available to us to make a solid conclusion.
Taken together, tumor-associated differences in spleen 
 [68Ga]Pentixafor uptake might be more relevant in some 
entities rather than all solid cancers. Moreover, based on 
our data, we think that spleen  [68Ga]Pentixafor uptake 
should be interpreted on a patient-to-patient basis even 
within the same tumor entity. However, more data needs 
to be collected to assess whether spleen  [68Ga]Pentixa-
for uptake is related to clinical outcomes and to estimate 
the clinical and therapeutic consequences, especially in 
patients undergoing immunotherapy.
Of course, due to the retrospective nature of this study, 
further limitations need to be taken into consideration. 
We did not have the chance of follow-up PET/CT imag-
ing of our patients and can thus not compare, whether 
changes in spleen CXCR4 expression during/after treat-
ment would implicate changes in clinical parameters or 
outcomes. In addition, patients were partially selected 
for imaging with  [68Ga]Pentixafor due to their relapsed 
disease and unfavorable prognosis. This could have led 
to a selection bias. Moreover, for some entities only very 
few patients were available and a bias due to these small 
cohorts needs to be taken into account. Lastly, other fac-
tors influencing spleen uptake values in patients, e.g. 
technical reasons during the application, different phar-
macokinetics and possibly differences in hepatic metabo-
lism and uptake consequently influencing the SLR need 
to be taken into account. However, our study provides 
the first investigation of spleen  [68Ga]Pentixafor uptake 
in a large cohort of 145 solid tumor patients and 5 non-
cancer control patients. We show spleen  [68Ga]Pentixafor 
uptake is not associated with survival, but positively 
associated with leukocyte and/or platelet counts in neu-
roendocrine, NSCLC and SCLC, possibly attributed 
to an activated state of spleen and/or elevated tumor 
metabolism/activity.
Conclusion
Spleen  [68Ga]Pentixafor uptake was not associated with 
PFS, OS or current disease remission status in a large 
cohort of 145 solid cancer patients. Furthermore, prior 
systemic treatment was not associated with increased 
or decreased spleen  [68Ga]Pentixafor uptake levels. 
However, we identified platelet counts and/or leukocyte 
counts to be positively correlated with spleen  [68Ga]Pen-
tixafor uptake in neuroendocrine tumors, NSCLC and 
SCLC. Further investigations need to clarify the mecha-
nism underlying the highly variable  [68Ga]Pentixafor 
uptake within the spleen of cancer patients.
Methods
Patient inclusion criteria
We retrospectively evaluated all  [68Ga]Pentixafor-PET 
images of solid cancer patients, available to us. In total, 
we could collect data of 145 patients with solid cancers 
representing 27 different tumor entities. Furthermore, 
 [68Ga]Pentixafor-PET images of 5 control patients were 
available to us. Of these, 3 patients were diagnosed 
with Conn’s adenoma and 2 patients were diagnosed as 
healthy. The patient characteristics of this cohort are 
detailed in Table 1.
Synthesis of  [68Ga]Pentixafor and imaging using  [68Ga]
Pentixafor
All patients in this study were imaged between Janu-
ary of 2013 and October of 2018 in the facilities of Uni-
versitätsklinikum Würzburg, Würzburg, Germany and 
Klinikum rechts des Isar, Munich, Germany. We retro-
spectively evaluated  [68Ga]Pentixafor-PET images from 
our database of patients that had been previously pub-
lished. Synthesis and imaging of patients was performed 
as previously described [15, 21, 43, 51–53]. All patients 
were imaged 60 min after an injection and dosage ranged 
from of 64 to 345 MBq (available from 141 patients and 5 
controls). Patients received a dosage of MBq of Pentixa-
for.  [68Ga]Pentixafor was administered in accordance to 
the German Medicinal Products Act, AMG §13 2b, and 
with permission of the responsible regulatory authorities 
(Regierung von Oberbayern, Regierung von Oberfranken 
and Regierung von Unterfranken) and the respective eth-
ics committees of Universitätsklinikum Würzburg and 
Klinikum rechts des Isar.
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Calculation of spleen‑to‑liver ratio (SLR)
Splenic  [68Ga]Pentixafor uptake was measured by placing 
a volume of interest (VOI) around the whole spleen and 
applying isocontouring until no extra-splenic structures 
were included in the VOI. Liver uptake was measured by 
placing a VOI of at least 30 mm in healthy hepatic tissue. 
Spleen and liver VOI were matched. To account for inter-
individual variance of tracer biodistribution, we normal-
ized spleen uptake by calculating a spleen-to-liver ratio 
(SLR). SLR was derived by dividing the maximum SUV of 
the spleen  (SUVmaxSpleen) by the mean SUV of the liver 
 (SUVmeanLiver).
Formation of groups for survival analysis
To assess the probability of survival, we conducted two 
separate analyses. First, we calculated the median SLR 
for  [68Ga]Pentixafor as explained above using Graph-
Pad Prism Version 9.0.1 (GraphPad Prism Software, La 
Jolla, CA, USA).within the respective cohorts. Patients 
were then allocated according to the median to a high 
and low group of spleen CXCR4 expression. Secondly, 
we assessed larger cohorts by forming two groups repre-
senting the highest and lowest quartile of spleen CXCR4 
expression as measured by SLR for  [68Ga]Pentixafor.
Laboratory parameters
We collected laboratory parameters from the day of 
imaging, wherever these were available to us, for serum 
C-reactive protein (mg/dl) (n = 132), serum lactate-dehy-
drogenase (LDH) (U/l) (n = 126), hemoglobin levels (g/
dl) (n = 143), peripheral leukocyte count (/nl) (n = 143) 
and peripheral platelet count (/nl) (n = 143).
Disease stage and remission status
To determine disease stage we collected information on 
the TNM stage of all solid cancer patients and grouped 
patients into limited disease stage, whenever they were 
classified with T1 or T2 stage and did not have any dis-
tant metastases (M0). Accordingly, patients with T3 or 
T4 stage, as well as subjects with distant metastases (M1) 
were classified as advanced stage. All patients for whom 
the exact allocation to limited or advanced disease was 
not possible were classified as unknown. We additionally 
evaluated patients upon their subsequent patient records 
and grouped them wherever possible into complete 
remission, partial remission, stable disease and progres-
sive disease.
Systemic treatment prior to imaging of patients
We retrospectively evaluated patient records. Prior 
treatments included chemotherapy, radiotherapy and 
surgery, as well as combinations of the aforementioned. 
One patient additionally received immunotherapy. To 
evaluate whether systemic treatment would influence 
 [68Ga]Pentixafor uptake, we compared those patients 
without ongoing systemic chemotherapy to those who 
had undergone systemic chemotherapy within the last 
month prior to imaging.
Statistics and graphical display of data
All analyses were performed using GraphPad Prism 
Version 9.0.1. (GraphPad Prism Software, La Jolla, CA, 
USA) and figures were constructed using InkScape 
Version 0.92.3 (Inkscape Project, open source). Quan-
titative variables were described as mean values ± 1 
standard deviation. PFS and OS were estimated using 
the Kaplan–Meier method and compared between 
groups with the log-rank test. Associations between 
continuous variables were analyzed with a linear 
regression model and depicted as scatter plots includ-
ing regression line and R2 value, indicating the coef-
ficient of determination. For all analysis, two-sided p 
values < 0.05 were considered significant.
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